Hims & Hers Health, Inc. ( NYSE:HIMS – Get Free Report ) has been assigned an average rating of “Hold” from the sixteen research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and seven have assigned a buy recommendation to the company.
The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $20.71. Several brokerages have issued reports on HIMS.
Canaccord Genuity Group upped their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th.
Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th.
Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th.
Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company.
Finally, TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday. Check Out Our Latest Research Report on HIMS Hims & Hers Health Stock Down 7.
4 % Hims & Hers Health ( NYSE:HIMS – Get Free Report ) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.
06 by $0.26. Hims & Hers Health had a return on equity of 10.
97% and a net margin of 8.19%. The company had revenue of $401.
56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm earned ($0.
04) earnings per share. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis.
Analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year. Insider Activity at Hims & Hers Health In other news, COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction on Monday, November 18th.
The shares were sold at an average price of $21.04, for a total transaction of $1,236,100.00.
Following the completion of the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at $13,258,692.64. The trade was a 8.
53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link . Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Tuesday, September 3rd.
The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28.
Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The trade was a 84.
94 % decrease in their position. The disclosure for this sale can be found here . Insiders sold a total of 1,056,183 shares of company stock worth $21,501,682 over the last quarter.
17.71% of the stock is owned by corporate insiders. Institutional Trading of Hims & Hers Health Hedge funds have recently bought and sold shares of the stock.
Nisa Investment Advisors LLC grew its stake in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares in the last quarter.
Quest Partners LLC grew its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the period.
CWM LLC grew its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period.
Van ECK Associates Corp acquired a new position in Hims & Hers Health during the second quarter worth about $111,000. Finally, Quarry LP raised its stake in Hims & Hers Health by 91.0% during the third quarter.
Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after purchasing an additional 2,913 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.
About Hims & Hers Health ( Get Free Report Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. Featured Stories Five stocks we like better than Hims & Hers Health Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy What Investors Need to Know to Beat the Market Williams-Sonoma Stock: Buy It and Never Let It Go How to Evaluate a Stock Before Buying 5 Dividend ETFs to Buy and Hold Forever Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.
com's FREE daily email newsletter ..
Business
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Brokerages
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has been assigned an average rating of “Hold” from the sixteen research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and seven have assigned a buy recommendation [...]